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Context: Cocaine- and amphetamine-regulated transcript (CART) codes for a peptide widely dis-
tributed in nervous and endocrine tissues. CART immunoreactivity (CART-LI) has been detected in
human insulinomas.
Objective: The objective of the study was to investigate the measurement of plasma CART-LI as a
tumor marker of neuroendocrine malignancy.
Design and Subjects: Plasma CART-LI levels were measured in 401 patients with a range of diag-
noses: neuroendocrine malignancy (n  131), after removal of neuroendocrine malignancy (n 
27), without any form of tumor or renal impairment (n 192), with renal impairment (n 17) and
with nonneuroendocrine tumors (n  34). Chromatography methods were used to investigate
CART-LI circulating in human plasma.
Results: The upper limit of normal calculated for CART-LI was 150 pmol/liter. Mean circulating
plasmaCART-LI amongneuroendocrine tumor patientswas 440 pmol/liter, 56%of subjects having
levels greater than 150 pmol/liter. Measuring CART-LI in addition to chromogranin (Cg)-A im-
proved the sensitivity for neuroendocrine malignancy from 85 to 91%, whereas combined use of
CgAandCgBhad a joint sensitivity of 89%.Of 38 patientswith pancreatic neuroendocrine tumors,
71% had plasma CART-LI levels greater than 150 pmol/liter, increasing to 95% in those classified
with progressive disease (n  20, mean CART-LI 625 pmol/liter), compared with 80% for CgA.
Chromatographic analysis suggests that circulating CART-LI is present as one major form, which
may correspond to CART (62–102) or another unknown form.
Conclusions: We demonstrate CART-LI as a specific tumor marker in patients with a range of
neuroendocrine tumors. Used in combination with CgA, CART-LI measurement has the potential
to improve sensitivity in diagnosis and follow-up of neuroendocrine tumors, in particular progres-
sive pancreatic neuroendocrine tumors. (J Clin Endocrinol Metab 93: 1246–1253, 2008)
Neuroendocrine cells are generally defined by the productionof a neurotransmitter, neuromodulator, or neuropeptide
hormone; the presence of dense core secretory granules from
which hormones are released by exocytosis in response to ex-
ternal stimuli; and the absence of axons and synapses (1). Out-
side the brain, the main source of regulatory peptides is from
diffuse neuroendocrine components of the gastroenteropancre-
atic system (2).
Neuroendocrine tumors are a heterogeneous group, secreting
a variety of peptides and biogenic amines. Functioning neuroen-
docrine tumors are characterized by various endocrine profiles,
which may give rise to recognizable clinical syndromes. In par-
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ticular, subtypes of pancreatic neuroendocrine tumors have been
defined by their specific production of hormones such as insulin,
glucagon, vasoactive intestinal polypeptide, and gastrin (3, 4).
More than50%ofneuroendocrine tumors are carcinoid tumors.
Most commonly originating in the midgut, these are defined by
characteristicmorphology and staining patterns but also by their
ability to synthesize serotonin (5, 6).
Originally discovered as a transcript up-regulated in the rat
nucleus accumbens in response to psychostimulant administra-
tion, cocaine- and amphetamine-regulated transcript (CART)
and the peptide it codes for have since been detected in the cen-
tral, peripheral, and enteric nervous systems and a number of
endocrine tissues, including the pancreas (7). CART is highly
conserved between species (8). CART (55–102) is the putative
active peptide; however, variable processing by prohormone
convertase enzymes gives rise to multiple CART fragments (9,
10). The CART system has been suggested to play a role in a
number of physiological and pathophysiological functions, in-
cluding regulation of feeding, drug abuse, stress, depression, and
insulin secretion (11–13).
CART is also produced by a variety of islet-derived trans-
plantable tumors (14), and CART immunoreactivity (LI) has
been demonstrated within human insulinomas (12). We there-
fore investigated the possible use of plasma CART-LI concen-
trations as a tumor marker of neuroendocrine malignancy.
Patients and Methods
Reference range data
To determine whether patients needed to be fasted before plasma
samples were taken for CARTmeasurement, the effect of food intake on
plasmaCART levelswas examined.Agroupof 12 volunteers (fivemales,
seven females, age ranging from 22 to 35 yr) who had fasted overnight
had levels measured 30 min before and 30, 60, 80, 100, 120, 150, and
180 min after a test breakfast. The meal comprised of two eggs, toast,
marmalade, and orange juice and contained approximately 560 kcal.
After the results of this study, the normal range of plasmaCART-LI level
was determined using samples collected from 29 healthy volunteers (19
females and 10males, mean age 32 yr). Circulating CART-LI levels have
reported to showa circadian rhythm in rats (15). CART-LIwas therefore
measured in a group of ad libitum-fed volunteers (n 5) at 0900, 1200,
1500, and 1800 h.
Patients and blood samples
CART-LI levels were measured in plasma samples from 131 patients
with neuroendocrine tumors derived from a range of sites; midgut (n
51), pancreatic (n  38), unknown primary (n  24), hindgut (n  5),
pulmonary (n 5), thymic (n 2), paraganglionic (n 2), gastric (n
2), ovarian (n  1), and renal (n  1). Patients were divided into those
with stable disease (n68) or progressive disease (n63). Patientswere
categorized into progressive disease if they had increase in size of tumor
and/or experienced worsening symptoms, requiring increased manage-
ment. Patients with stable disease were described as having stable symp-
toms and/or no growth in tumor size. Treatments that patients received
included somatostatin analogs, I131-metaiodobenzylguanidine therapy,
capecitabine, interferon, cisplatin, and yttrium 90-labeled octreotide
treatment. Results were compared with those using chromogranin
(Cg)-A and CgB assays.
To see whether CART-LI measurement could aid in the detection of
nonfunctioning neuroendocrine tumors, levels were also measured in
patients who had undergone complete removal of neuroendocrine tu-
mors (n  27) and in other cases including newly diagnosed pituitary
tumors (n  6), various nonneuroendocrine tumors (n  34), prostate
cancer (n 153), and patients with renal impairment (n 17). Patients
with a range of other conditions or complaints having blood tests at the
hospital phlebotomy department were also accepted and tested for
plasma CART-LI levels (n  192). Possible effects of age or sex on
circulating levels of CART-LI were analyzed using data, respectively,
from 132 of these patients whose age could be confirmed and a subset of
these patients whose sex could be confirmed.
Sample collection and storage
All blood samples were collected into heparinized tubes containing
400 kallikrein inhibitory units aprotinin (Trasylol; Bayer, UK) per mil-
liliter of blood and immediately centrifuged. Plasma was separated and
stored at20Cuntil assay. To assess the stability of CART-LI in human
plasma, six samples were taken from two subjects, half into lithium
heparin tubes containing Trasylol and half into lithium heparin tubes
withoutTrasylol. Before centrifugationand separationof theplasma, the
samples were left at room temperature for different lengths of time up to
8 h and then stored at 20 C.
RIA
An establishedRIAdirected toCART55–102was used as previously
described (16). Briefly, CART 55–102 was purchased from the Peptide
Institute (Osaka, Japan).Theantiserumwas raised ina rabbit immunized
with human CART (55–102) peptide conjugated to BSA by glutaralde-
hyde (17). The 125I-labeled synthetic CART (55–102) was prepared by
the direct iodogen method and purified by reverse-phase HPLC.
The assay had a sensitivity of 1.9 0.5 fmol/tube (means SEM), n
5,with 95%confidence interval. The specific activity of freshly prepared
CART (55–102) peptide label, as estimated by self displacement in the
assay, was 58 Bq/fmol. A standard curve of 10–50 fmol/tube of CART
(55–102) was set up in conjunction with dilutions of four samples from
patients with high levels of CART-LI. The resulting binding curves
showed good parallelism (data not shown). The interassay variation at
157pmol/liter (15.7 fmol/tube, n14)was 8%and426pmol/liter (42.6
fmol/tube, n  14) was 7%. The intraassay variation at 157 pmol/liter
varied from 4 to 9% (n 5), and at 426 pmol/liter, the range was from
8 to 12% (n  5).
CgAandCgBassayswere carriedoutusingantibodies raised todetect
pancreastatin forCgAandglycine-alanine-tryptophan-lysine (CgB420–
493) fragment for CgB, as previously described (18, 19). Normal ranges
for CgA andCgB are less than 60 pmol/liter and less than 150 pmol/liter,
respectively.
Peptide extraction procedure
Peptide was extracted from plasma using Sep-Pak C18 cartridges
(Waters, Milford, MA) as previously described (20).
Chromatography
CART-LI was characterized as previously described by gel chroma-
tography and reverse-phase fast protein liquid chromatography (FPLC)
eluting with an 18–24% gradient of acetonitrile/water 0.05% (vol/vol)
trifluoroacetic acid over 50 min (21). Elution coefficient (Kav) for all gel
chromatography elution profiles was calculated also as previously de-
scribed (21).
Statistics
One-way ANOVAwas used to assess the variation in plasma CART
levels among healthy volunteers throughout the day. Independent Stu-
dent t tests were used to compare mean CART-LI levels between groups
of patientswith stable and progressive disease and between patientswith
midgut or pancreatic neuroendocrine tumors.
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Ethics
All subjectswith neuroendocrine tumorswere anonymized. All other
subjects in the study gave written informed consent for themeasurement
of CART-LI in plasma samples, and ethical approval was obtained from
the Hammersmith and Queen Charlotte’s and Chelsea Hospitals Re-
search Ethics Committee (no. 04/Q0406/80). Studies were performed in
accordance with the Declaration of Helsinki. Blood was taken from all
subjects between 0900 and 1200 h.
Results
Reference range
The mean plasma CART-LI level among the 29 healthy vol-
unteers fromour laboratorywas 80pmol/liter (SD 30). The upper
limit of normal was calculated as 150 pmol/liter, based on
mean  2 SD, and rounded to the nearest 50 pmol/liter. Hence-
forth, where normal or raised CART-LI levels are referred to, it
is based on this reference range. There was no significant change
in themean plasmaCARTof 12 volunteers after consumption of
a 560-kcal meal, suggesting that circulating CART levels are not
acutely affected by food intake (Fig.1). Also, there was no sig-
nificant variation in plasmaCART levelmeasured in five healthy
volunteers throughout the day [0900 (fasting), 1200, 1500, and
1800 h]. Plasma samples from two subjects showed no decrease
in CART-LI when left at room temperature for up to 8 h. The
addition of Trasylol to lithium heparin tubes made no difference
in CART-LIwhen comparedwith lithium heparin tubeswithout
Trasylol.
Chromatography
Samples from subjects with high- and low-plasma CART
were fractionated using G-50 Sephadex chromatography. All
columns had a recovery of more than 70%. CART 55–102 and
CART 61–102 standards elute with a Kav of 0.50 and 0.44,
respectively. Three different plasma samples from normal sub-
jects were fractionated by gel chromatography (n  3); Fig. 2A
shows a representative elution profile of plasma CART-LI of
this. The singleCART-LI peak detected eluteswith aKav of 0.56.
Figure2B showsa representative (n4) elutionprofile ofplasma
CART-LI from a subject with high levels of plasma CART-LI.
Two peaks were detected. The first contains 14% of total
CART-LI detected and elutes with a Kav of 0.26, giving it a
molecular weight of approximately 12,500. The second larger
peak contains 86% of total CART-LI detected and elutes with a
Kav of 0.56, corresponding to the single peak detected in Fig. 2A.
Reverse-phase FPLC
Reverse-phase C-18 FPLC chromatography was used to fur-
ther analyze CART-LI in human plasma. All columns had a re-
covery greater than 72%. CART 55–102 and CART 61–102
standards eluted at 20.8 and 20.4% acetonitrile, respectively.
Figure 2C shows a representative (n  4) elution profile of ex-
tracted plasma CART-LI from a subject with normal circulating
CART-LI levels. The single CART-LI peak detected elutes with
20% ACN. Figure 2D shows a representative (n  5) elution
profile of extracted plasma CART-LI from a subject with high
circulating CART-LI levels. The single CART-LI peak detected
also eluteswith20%ACNand thus corresponds to theCART-LI
peak detected in plasma from normal subjects. To determine
whether the first peak in Fig. 2B could be resolved further, the
fractions containing this peak were dried down in a Savant vac-
uum centrifuge, reconstituted in distilled water and 0.05% (vol/
vol) trifluoroacetic acid and fractionated by reverse-phase C-18
FPLC. Figure 2E shows a representative (n 3) elution profile of
the CART-LI peaks detected. The first contains 80%of the total
CART-LI detected and elutes at 19.6% ACN. The second two
peaks both contain 10%of the total CART-LI detected and elute
at 21.0 and 41.6% ACN.
CART-LI levels in neuroendocrine tumor patients
Overall, CARTwas positive in 73 of the 131 neuroendocrine
tumor cases tested (56%). Of the main tumor types, CART was
raised in 23 midgut tumor cases (45%), 27 pancreatic tumors
(71%), and 15 tumors of unknown origin (63%). Ninety-five
percent of patients with progressive pancreatic neuroendocrine
tumors had raised plasma CART-LI levels (n  20). Mean
plasmaCART-LI levelswere significantly higher among patients
with progressive disease (n 63), compared with patients with
stable neuroendocrine tumors of all types (n  68) (P  0.035)
(Table 1). A comparison of gastrointestinal neuroendocrine tu-
mors (NETs) (n  58), pancreatic neuroendocrine tumors (n 
38), and nongastrointestinal NETs (n  11) revealed that pan-
creatic neuroendocrine tumors have a significantly (P 0.0402)
higher mean CART-LI level (540  66 pmol/liter) than gastro-
intestinal NETs (337 51 pmol/liter); however, there is no sig-
nificant difference between pancreatic neuroendocrine and non-
gastrointestinal NETs (510 136 pmol/liter) (mean SEM). All
27 cases under observation after the removal of a neuroendo-
crine tumor had plasma CART-LI within the normal range.
Comparing and combining CgA and CART assays
Eight neuroendocrine tumor cases were identified with
CART-LI greater than 150 pmol/liter but normal CgA: five tu-
mors of pancreatic origin and one each of unknown, lung, and
hindgut origin. Forty patients had CART levels greater than
1000 pmol/liter; 13 (34%)withmidgut neuroendocrine tumors,
and 12 (30%) with neuroendocrine tumors of pancreatic origin.
In comparison, such high levels of CgA (1000 pmol/liter) were
more commonly from midgut tumors (46%) and less so from
FIG. 1. Mean plasma CART-LI level of 12 subjects before and after consumption
of a test meal.
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pancreatic neuroendocrine tumors (13%). CART-LI has 95%
sensitivity for progressive pancreatic neuroendocrine tumors,
compared with only 80% sensitivity for CgA. Combined use of
CgA and CART assays gave a positive result in 91% of cases,
comparedwith 85%usingCgA assay alone. The combinedmea-
surement of CgA and CgB had a lower sensitivity of 89%.Mea-
suring CgA, CgB, and CART-LI did not improve the sensitivity
over that of CgA in conjunction with CART.
CART-LI levels in patients without neuroendocrine tumors
Of 192 patients without tumors or renal impairment [93 fe-
males and 100males, average age 53 yr (SD 18 yr)], only one had
FIG. 2. Sephadex G-50 column chromatography showing representative elution profiles of plasma CART-LI from a healthy subject, 75 pmol/liter (A) and plasma from a
patient with a high level of CART-LI, approximately 20,000 pmol/liter (B). CC, Elution position of horse heart cytochrome C; 61, elution position of CART (61–102); 55,
elution position of CART (55–102). Representative FPLC profiles of plasma CART-LI taken from a healthy subject (C), plasma from a patient with a high level of CART-LI
(D), profile of fractions containing first peak (E) from B. Solid line, CART-LI concentration; broken line, percent ACN.
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raised CART-LI levels (Fig. 3). Overall, themeanCART-LI level
for the groupwas 76 pmol/liter (SD 30 pmol/liter). Renal impair-
ment was associated with an increase in plasma CART-LI. The
mean level among a group of 17 such patientswas 200 pmol/liter
(SD 33 pmol/liter),with amaximumvalue of 282pmol/liter (with
glomerular filtration rate 16 ml/min).
Of 34 patients with nonneuroendocrine tumors and normal
renal function, threewere found tohave elevated levelsofCART-
LI. These were adenocarcinomas of the bowel (159 pmol/liter),
pancreas (457 pmol/liter), and prostate (393 pmol/liter) (Table
2). The mean CART-LI level among 153 samples from patients
with prostate cancer was 84 pmol/liter (SD 38 pmol/liter). Seven
had raised plasma CART-LI levels, up to a maximum of 226
pmol/liter, although renal function was unknown.
CART-LI levels measured in 132 subjects aged 18–89 yr did
not correlate with age (r2  0.0904). There was also no signif-
icant difference in CART-LI levels between 49 male (72  2.8
pmol/liter) and49 female (743.8pmol/liter) patients (mean SEM).
Discussion
A substantial proportion of neuroendocrine tumors not associ-
ated with specific hormonal markers or clinical syndromes, pre-
viously defined as nonfunctioning, may still be secretory. A ma-
jor advancement in the diagnosis of neuroendocrine tumors, and
the screening of individuals predisposed to neuroendocrine ma-
lignancy, has been the discovery of nonspecific markers such as
CgA and CgB (18, 19, 22–24). CgA, cosecreted with amines and
peptides, is generally accepted as the best available neuroendo-
crine tumor marker (25, 26). However, CgA is not 100% sen-
sitive for neuroendocrine tumors, and consequently, there is a
need for additional nonspecific tumor markers (27).
We report for the first time increased CART-LI in patients
with neuroendocrine malignancy. Raised in many forms of neu-
roendocrine tumor, high levels were associated particularly with
those of pancreatic origin, with up to 95% of patients with in
progressive pancreatic neuroendocrine tumors having raised cir-
culating CART-LI. This is in accord with previous reports de-
scribing the presence of CART in insulinomas and gastrinomas
as well as healthy islet cells (12). In the current study, CgA was
FIG. 3. CART-LI level against age for 192 patients without known or suspected
neuroendocrine tumors, in the absence of known renal impairment or other form
of cancer. F, Male; E, female.
TABLE 1. Mean plasma CART-LI concentration (picomoles per liter), SD, number of patients with positive test, and sensitivity of
CART, CgA, and CgB assays against disease status (stable or progressive) of patients with known neuroendocrine tumors
Site of NET
Disease
status n
CART CgA CgB
Mean
(SD)
ve
(%)
Mean
(SD)
ve
(%)
Mean
(SD)
ve
(%)
Midgut Stable 24 250 (348) 7 (29) 490 (342) 24 (100) 120 (43) 6 (25)
Progressive 27 447 (429) 16 (60) 697 (396) 25 (93) 147 (57) 12 (44)
Pancreatic Stable 18 426 (443) 8 (44) 352 (409) 12 (67) 168 (114) 11 (61)
Progressive 20 625 (348) 19 (95) 379 (362) 16 (80) 166 (57) 12 (60)
Unknown primary Stable 12 520 (455) 7 (58) 622 (362) 12 (100) 202 (114) 8 (67)
Progressive 12 606 (434) 8 (67) 794 (338) 11 (92) 209 (76) 9 (75)
Hindgut Stable 4 279 (326) 2 (50) 361 (438) 3 (75) 142 (27) 1 (25)
Progressive 1 70 0 (0) 141 1 (100) 89 0 (0)
Lung Stable 4 532 (540) 2 (50) 299 (468) 2 (50) 127 (85) 2 (50)
Progressive 1 270 1 (100) 60 0 (0) 49 0 (0)
Thymic Stable 2 58 (27) 0 (0) 37 (5) 0 (0) 61 (9) 0 (0)
Progressive 0
Para-ganglioma Stable 1 1000 1 (100) 153 1 (100) 196 1 (100)
Progressive 1 1000 1 (100) 184 1 (100) 161 1 (100)
Gastric Stable 2 133 (103) 1 (50) 124 (77) 2 (100) 133 (29) 1 (50)
Progressive 0
Ovary Stable 1 77 0 (0) 1000 1 (100) 157 1 (100)
Progressive 0
Renal Stable 0
Progressive 1 74 0 (0) 50 0 (0) 180 1 (100)
All sites Stable 66 372 (411) 28 (42) 448 (383) 57 (86) 150 (88) 30 (46)
Progressive 54 535 (419) 36 (67) 592 (420) 46 (85) 167 (65) 32 (60)
CART ve, Plasma CART-LI greater than 150 pmol/liter; CgA ve, plasma CgA greater than 60 pmol/liter; CgB ve, plasma CgB greater than 150 pmol/liter.
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particularly sensitive formidgut tumors and tumors of unknown
origin,whichoftenhavea similarnatural history to thosederived
from the midgut (28). This pattern has been shown previously,
with highest levels of CgA found in patients with carcinoid tu-
mors (22). In accordwith this, positive immunostaining for CgA
is found in virtually all enterochromaffin cells but is not universal
among neuroendocrine tumors (29, 30). Such evidence supports
the use of additional tumor markers as adjuncts to CgA to max-
imize the sensitivity of immunohistochemical diagnosis. In our
center CgB is measured routinely as a complement to CgA, and
other centers have reported similar use ofCgB assays (31). In this
study, combined use of CgA and CART assays also gave a pos-
itive result for a greater number of neuroendocrine tumor pa-
tients than combining CgA and CgB, suggesting a greater cross-
over of tumors producing both CgA and CgB than CgA and
CART.
Circulating neuroendocrine tumor markers are useful in not
only the diagnosis of tumors but also patient follow-up and the
classification of disease status (32). The results of this study
showed significant difference in plasmaCART-LI levels between
patients with stable and progressive disease. This suggests that
CART-LI, like CgA, might be used to help monitor treatment
response, whether the aim is curative or simply to slow disease
progression. To further define the potential use of CART-LI
measurement as a marker in neuroendocrine tumors, it will be
necessary to conduct longitudinal studies and examine the effect
of tumor resection on circulating levels of CART-LI. It would
also be useful to investigate whether treatments such as soma-
tostatin analogs influence CART-LI levels.
Our results demonstrated that CART-LI was not only sensi-
tive for neuroendocrine disease but also specific.Only oneof 192
patients without tumor or renal impairment had a raised plasma
CART-LI level of 171 pmol/liter. This patient had a history of
cluster headaches and was being investigated for suspected in-
flammatory bowel disease.We found that, asmight be expected,
renal impairment was associated with an elevation of plasma
CART-LI. However, levels were not as high as those found in
neuroendocrine tumor patients. Inflammatory bowel disease
and renal impairment are also associated with raised circulating
CgA (27). Three of 34 patients with nonneurendocrine tumors
had CART-LI levels above the normal range, with primary tu-
mors of the bowel, prostate, and pancreas. The highest levels
were seen in the patients with the tumors of the prostate and
pancreas. Neuroendocrine differentiation of prostatic carcino-
mas is a recognized factor affecting prognosis, and elevated CgA
values correlate with aworse outcome (33, 34). Of a further 153
blood samples from prostate tumor patients, 5% had elevated
plasma CART-LI. As renal function was unknown, these results
must be treated with caution. The mean CART-LI level of five
patients with nonneuroendocrine pancreatic tumors was 150.2
pmol/liter. This was the highest level of all the nonneuroendo-
crine tumors.Neuroendocrinedifferentiation is a recognized fea-
ture of pancreatic tumors and is also associatedwith a rise inCgA
in certain patients (26).
In rats, circulatingCARTpeptide exhibits adiurnal variation,
with peak levels in the evening. In contrast, CART levels in the
rhesus monkey are higher in the morning. In both species, the
diurnal rhythm corresponds with changes in circulating glu-
cocorticoids (15, 35). Strong evidence suggests that hypotha-
lamic CART is associated with the regulation of the hypotha-
lamic-pituitary-adrenal axis in animal models (11, 16, 35).
PlasmaCART-LI levels in the fivehealthyvolunteers in this study
did not significantly differ throughout the day, and comparisons
between individuals showed no standard pattern of diurnal vari-
ation. There was no correlation with plasma cortisol levels. In
addition, there was no effect of fasting or feeding on circulating
CART-LI levels. PlasmaCART-LImay therefore play a different
role in humans, compared with other mammals.
Size exclusion chromatography and FPLC analysis suggests
that CART-LI circulates in human plasma in one major form.
Using size exclusion chromatography, this form eluteswith aKav
of 0.56. There may also be small quantities of other CART-LI
fragments in plasma because we detected a smaller additional
peak eluting with a Kav of 0.26 in patients with very high levels
of CART-LI. It is possible that this peak is also present in normal
subjects, but there is insufficient present in the sample to be
detected. This fraction elutes slightly earlier than cytochrome C,
which has a molecular weight of 12,384, suggesting this peak
may represent a protein with a similar molecular weight. It is
possible that this peak represents preproCART.Kuhar andYoho
(36)previouslydetecteda fragmentofCART in rat adrenal gland
with a molecular mass of approximately 13.5 kDa by Western
blotting,which they proposed could be preproCART.Neither of
the elution positions of the CART-LI peaks in our studies cor-
respond with CART (55–102) or CART (61–102). CART (62–
102) is not commercially available, and it is therefore possible
that the peak represents this formofCARTpeptide, although the
large difference in Kav between plasma CART-LI and CART
(61–102)would suggest otherwise. FPLCanalysis also suggested
that there is one major CART fragment in human plasma. The
TABLE 2. Mean plasma CART-LI concentration (picomoles per liter), SD, range, and number of patients testing positive by the
assay (150 pmol/liter) in patients with a range of non-NETs
Tumor site No. of patients Mean plasma CART-LI SD Range CART ve
Throat 4 84.0 5.9 79.0–92.0 0
Testicle 2 61.7 7.8 56.2–67.2 0
Bowel 5 93.2 39.9 57.9–159.0 1
Prostate 8 105.3 117.0 50.0–392.5 1
Brain 4 88.2 38.2 53.3–138.8 0
Bladder 2 99.7 37.2 73.3–126.0 0
Breast 4 83.1 31.5 70.0–138.1 0
Pancreas 5 150.2 171.8 56.0–456.6 1
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CART-LI peak detected in plasma from normal subjects corre-
sponded to the peak detected in plasma from patients with high
levels of CART-LI but again did not correspond to CART (55–
102) or CART (61–102).
Circulating forms of CART peptide have previously been
analyzed using surface-enhanced laser desorption ionization-
time-of-flight mass spectrometry in a study by Yanik et al.
(37), who detected small amounts of a peptide with a similar
molecular weight to CART (55–102) and higher levels of a
peptidewith a similarmolecular weight to CART (62–102). In
view of these results, it is possible that the single major peak
detected in our study does correspond to CART (62–102).
Yanik et al. also detected two smaller additional fragments
with larger molecular weights that they proposed might rep-
resent intermediate forms of CART peptide. It is possible that
the techniques used in our study are insufficiently sensitive to
detect the low levels of other forms of CARTpeptides reported
in the previous study. It is also possible human CART may be
posttranslationally modified. Further studies are necessary to
characterize this possible modification in more detail. CART
(1–89) and CART (10–89) extracted from rat adrenal glands
are believed to have an unknown posttranslational modifica-
tion, adding approximately 80 mass units to their molecular
weight (38). Further fractionation by FPLC of the first peak
obtained by size exclusion chromatography separated three
peaks, none of which corresponded to the CART peptide
standards.
Studies conducted by Koylu et al. (39) found CART peptide
levels were higher in males than females and that CART levels
increased with age. In our studies we found no significant dif-
ference in circulating CART levels with age or sex. It is possible
subtle differences in the patient groups account for the discrep-
ancies between these results.
Plasma CART-LI may represent a new tumor marker of
neuroendocrinemalignancy. Although less sensitive thanCgA
as a general marker of neuroendocrine tumors, the combined
sensitivity of CART-LI and CgA is better than that of CgA and
CgB. There is a particular association of CART-LI with neu-
roendocrine tumors of pancreatic origin. Further studies are
now required to fully assess the value of measuring plasma
CART-LI as an adjunct to CgA in the diagnosis of neuroen-
docrine disease.
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